Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)

Publisher Website
Google Scholar
Abstract
No abstract available